2025 Neuroscience Landscape Review: A focus on ALS, Epilepsy and MS

Explore the evolving Neuroscience drug development landscape across amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), and epilepsy. This review delivers a data-driven analysis of therapeutic modalities, priority biological targets, and key emerging assets shaping the next phase of CNS innovation.

The Neuroscience Drug Development Landscape

Download this in-depth review to access a comprehensive, data-driven analysis of the ALS, Multiple Sclerosis and Epilepsy drug development landscape. Stay ahead of the curve and gain unmatched insights into the fast-evolving world of Neuroscience drug development with Beacon Neuroscience.

Download Now

 

 

2025 Neuroscience Landscape Review

This Review Contains Key Insight Into:

  • Therapeutic modality diversification across CNS disorders: While small molecules remain foundational, RNA, gene, and cell therapies are increasingly prominent, reflecting a shift toward genetically and mechanistically driven intervention strategies.
  • ALS as a proving ground for RNA therapeutics: The pipeline is characterised by an expansion of multi-target platform-based antisense approaches targeting distinct genetic drivers, signaling maturation beyond single-target development.
  • Emerging epilepsy assets signal selective innovation: Recent pipeline entrants highlight cautious expansion beyond conventional anti-seizure mechanisms, with novel modalities being selectively explored for high-unmet-need patient populations.
  • MS pipelines signal confidence in progression-focused biology: BTK inhibition is emerging for progressive MS, and the steady increase in cell-based therapies indicates increased translational confidence and ongoing exploration of immune reset strategies.
  • Key assets and platforms to watch: Late-stage BTK inhibitors, novel RNA and gene therapies, and next-generation blood-brain-barrier (BBB) delivery technologies are poised to shape near-term clinical and strategic inflection points.

Download Now

Previous Neuroscience Landscape Reviews

2025 Neuroscience Landscape Review Feature Image

H1 2025 Neuroscience Landscape Review

Uncover the key H1 2025 neuroscience breakthroughs and stay ahead in a rapidly evolving landscape.

You May Also Be Interested In…

Learn More About Neuroscience

What is Beacon Neuroscience?
  • The Most Comprehensive Way to Search the Neuroscience Drug Development Landscape: Unique search ontologies based on Neuroscience drug and trial characteristics
  • Market Leading Approach to Neuroscience Preclinical & Clinical Data Curation: Manual curation of key Neuroscience research and development data points by Neuroscience research scientists
  • Seamlessly Integrate Commercial & Scientific Data all in One Place: Search Neuroscience company and deal data based on their pipeline and technologies.
  • Unrivalled Granularity in Reports & Analysis: Our search ontology and technology indexing enable comprehensive analysis not seen elsewhere.
Learn More About Beacon Neuroscience

What is Beacon?

Beacon is a world leading data analysis tool for preclinical and clinical trial information. With unrivalled granularity of search function, data quality, and exhaustiveness, Beacon provides timely information and gives you confidence to progress your targeted drug therapies to patients.

Learn more about how our clinical trials and drug database solutions can be tailored to your research requirements

Find out more

Menu
Search Icon
Close Icon
Search